Scholarlink

<p>Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月22日

查看全文
  • Kentaro Tanaka,
  • Jun Sugisaka,
  • Yoshimasa Shiraishi,
  • Yasutaka Watanabe,
  • Haruko Daga,
  • Koichi Azuma,
  • Kazumi Nishino,
  • Masahide Mori,
  • Takayo Ota,
  • Haruhiro Saito,
  • Akito Hata,
  • Tadashi Sakaguchi,
  • Toshiyuki Kozuki,
  • Hiroaki Akamatsu,
  • Hirotaka Matsumoto,
  • Motoko Tachihara,
  • Kazushige Wakuda,
  • Yuki Sato,
  • Tomohiro Ozaki,
  • Yuko Tsuchiya-Kawano,
  • Nobuyuki Yamamoto,
  • Kazuhiko Nakagawa,
  • Isamu Okamoto

摘要

Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.